

OSTEOPORE SIGNS COMMERCIAL COLLABORATION AGREEMENT WITH SINGULAR HEALTH

Highlights:

- *Osteopore Ltd has agreed to four multi-year licenses of the 3Dicom VSP and 3Dicom R&D software and are the first enterprise partner to provide 3Dicom VSP to their users.*
- *Enterprise licenses to be jointly branded within 3Dicom VSP and User Portal and Osteopore will actively promote the 3Dicom software to their extensive list of surgeons.*
- *Singular Health and Osteopore have agreed to jointly assess potential merger and acquisition (M&A) opportunities and collaborate on various business activities including marketing and sales in the USA and Australia.*
- *Osteopore and Singular Health remain committed to conducting previously announced comparative study, with Osteopore paying for further modifications to AI cranial model.*

1 August 2022: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce the signing of a collaboration agreement with Singular Health (ASX:SHG), focused on jointly assessing corporate M&A activities, the procurement of four enterprise licenses of 3Dicom VSP, and collaborating on business opportunities in the USA and Australia.

Enterprise Licenses of 3Dicom R&D and 3Dicom VSP

Following evaluation of the recently completed 3Dicom VSP module for Virtual Reality, whereby Osteopore and Singular staff remotely collaborated on cranial scans in real-time, Osteopore has agreed to four enterprise licenses of the 3Dicom R&D and VSP software. These four licenses will see Osteopore branding added to the 3Dicom User Portal for Osteopore’s surgeons and the ability for Osteopore’s surgeons to visualise the OSX products in Virtual Reality along with their own scans for training and marketing purposes.




Figure 1: The 3Dicom VSP software allows Osteopore to share virtual models of the cranium and cranial implants with end-users for training, educational and visualisation purposes anytime and anywhere.

Comparative Study and Development of Skirted AI Cranial Implant Model

As per the ASX Announcement (“OSX: Commences AI-Powered Design Study for Cranial Implants”) dated 14th March 2022, Singular and Osteopore continue to work on modifying the AI cranial implant model to suit the Osteopore manufacturing process with the addition of a ‘skirt’ and netting of the implant. This work continues to progress ahead of the planned comparative study in a clinical setting.




Figure 2: Osteopore's US Sales Manager, Kean Lee, and Singular Health's COO, James Hill, at American Association of Neurological Surgeons' (AANS) Annual Conference in Philadelphia in early-May 2022

Joint Assessment of Potential Corporate and Commercial Opportunities

Following separate representation at the American Association of Neurological Surgeon's (AANS) Annual Conference in the USA and discussions with numerous medical implant designers and manufacturers by Osteopore and Singular individually, many opportunities have arisen both at an operational/commercial level and at a corporate level.

With Osteopore providing both a cutting-edge material and manufacturing technique, and Singular Health providing design software and an integrated means for surgeons and designers to collaborate in future, the synergies of combining design and manufacture have already led to joint presentations and conversations by Osteopore and Singular Health to third parties in the USA, Australia, and Europe.

With both Singular and Osteopore already having informally facilitated introductions to third parties, today's collaboration agreement helps to formalise future collaborative activities as the Companies assess potential M&A opportunities in the USA, Australia, and Europe. These conversations steadily progress towards corporate and commercial outcomes.

Thomas Hanly, Singular Health Managing Director, said, "This agreement builds on our existing research collaboration with Osteopore and the CSIRO to build an Artificial Intelligence Tool that can design a Patient Specific Cranial Implant from a CT scan using our 3Dicom Software Suite. From that initial collaboration, the two companies have been active in reviewing and developing commercial opportunities using our software and Osteopore's bio-resorbable material in Australia, the USA, and South-East Asia.

The cranial AI tool built from our original agreement has now been complemented with a skirt or flange that conforms to the unique requirements of Osteopore's bio-resorbable material and reduces the time taken to design a patient specific implant from up to 3 hours to less than 30 minutes with custom edits. This positions the two companies squarely in the global cranial implant market which according to the December 2021 Global Cranial Implants Market Analysis (2021-2027) from KBV Research is valued \$1.679 Billion by 2027 with a combined annual growth rate of 11.5%."

Goh Khoo Seng, CEO of Osteopore, said, "This is an exciting opportunity as it allows Osteopore to provide a more holistic solution to our partners and surgeons. We hope to provide our partners and surgeons with the better quality tools to help improve the quality of patient care."

Additional Agreement Details

The collaboration agreement is effective 1 August 2022, for a term of 3 years. Each party will bear their own costs in relation to the collaboration. The costs of the enterprise licenses of the 3Dicom R&D and VSP software as well as the development of Skirted AI Cranial Implant Model are not expected to be material at this stage. The collaboration agreement contains termination provisions and other terms that are standard in agreements of this nature.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

About Singular Health

Singular Health Group Limited (ASX:SHG) is a medical technology company that empowers practitioners and patients via personalised surgical planning solutions that drive better health outcomes. Singular Health has developed a proprietary Volumetric Rendering Platform (VRP) that leverages existing 2D radiological images to generate fully immersive patient-specific 3D/VR models. Although Singular Health's VRP technology is applicable to other sectors in which the visualisation of dynamic data is crucial, with it already being utilised in the mining sector, the Company's core focus is on the medical sector.

Complementing its VRP technology, Singular Health has acquired Virtual Surgical Planning software and a 25% stake in medical-grade 3D printing company Additive Engineering. These investments represent key milestones in Singular Health's efforts to commercialise its 'Scan to Surgery' initiative, a world-first vertically integrated platform that revolutionises the planning and execution of personalised surgical procedures.

A successful full-scale commercialisation of this end-to-end personalised surgical planning platform will give Singular Health the capability to penetrate a multi-billion-dollar global market opportunity in the medical visualisation and additive manufacturing spaces.

With Singular Health, practitioners are empowered by having the ability to collaborate with producers of patient-specific medical components in real-time while patients benefit from having access to easily comprehensible and enhanced medical information.

To learn more, please visit: www.singular.health

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.